Get the Daily Brief
Latest Biotech News
$120M Series B fuels Pelage toward Phase III hair‑regeneration trials
Pelage Pharmaceuticals raised $120 million in a Series B led by ARCH Venture Partners and GV to advance its topical stem‑cell reactivation candidate PP405 into Phase III development. The company...
Roche picks up Hansoh ADC — $80M now, up to $1.45B in milestones
Roche struck a licensing agreement with Hansoh Pharma to acquire global rights to an early‑stage CDH17‑targeting antibody‑drug conjugate for colorectal cancer, paying an $80 million upfront and...
FDA names first CNPV winners — firms eye 1–2 month reviews
The U.S. Food and Drug Administration awarded the inaugural round of Commissioner’s National Priority Vouchers (CNPVs), selecting nine products from a mix of investigational drugs, approved-abroad...
Broad and Roche set new speed record — genome-to-result under four hours
Broad Clinical Labs, working with Roche and Boston Children’s Hospital, demonstrated an ultra-rapid whole-genome sequencing workflow that produces diagnostic-ready variant files in about four...
MD Anderson pins chemo resistance on tumor‑resident Fusobacterium
Researchers at MD Anderson Cancer Center reported that Fusobacterium nucleatum can invade tumor epithelial compartments and induce a reversible quiescent state that reduces epithelial signaling,...
Kite, Pregene ink up to $1.6B pact to push in vivo CAR‑T
Gilead’s Kite Pharma signed a research and licensing deal with China’s Pregene Biopharma worth up to $1.64 billion, including a reported $120 million upfront, to advance in vivo CAR‑T and...
Praxis’ tremor pill clears Phase 3 — company moves toward NDA
Praxis Precision Medicines reported that its oral candidate ulixacaltamide met primary and key secondary endpoints across two Phase 3 trials for essential tremor, with the company preparing a...
Big rounds revive hair and dermatology bets: Pelage and Veradermics raise hundreds
Two notable private financings signaled investor appetite returning to specialty biotechs. Pelage Pharmaceuticals closed a $120 million Series B to advance its hair‑follicle stem cell therapy...
Roche buys Hansoh ADC rights — licensing spree caps busy week
Roche agreed to acquire global rights to an early‑stage ADC from Hansoh Pharma for an $80 million upfront payment and up to $1.45 billion in milestones, gaining a CDH17‑targeted colorectal cancer...
Tumor‑on‑chip models advance CAR‑T for solid cancers — two Nature papers
Two independent studies published this week introduced vascularized tumor‑on‑chip platforms enabling controlled perfusion of human tumor explants with immune cells to interrogate CAR‑T function in...
AI disease models and generative systems move from lab to pipelines
Sophia Genetics rolled out a Digital Twins module inside its Sophia DDM cloud platform to simulate disease trajectories, treatment responses and survival outcomes using multimodal clinical,...
Manufacturing bet: Lonza gains Swiss GMP line; Merck buys JSR chromatography unit
Lonza received Swissmedic approval and a GMP license for a new aseptic drug‑product filling line in Stein (Switzerland), adding high‑containment capabilities for highly potent biologics including...
Broad, Roche break speed barrier: genome to result in under four hours
Broad Clinical Labs, in collaboration with Roche Sequencing Solutions and Boston Children’s Hospital, reported an ultra‑rapid whole‑genome sequencing workflow that produced variant calls in...
Kite doubles down on in vivo CAR‑T: $1.64B deal with Pregene
Kite Pharma (Gilead) struck a development and licensing agreement with China’s Pregene Biopharma to accelerate next‑generation in vivo CAR‑T therapies, committing up to $1.64 billion and an...
Praxis’ ulixacaltamide wins Phase 3 – NDA on deck
Praxis Precision Medicines reported that its oral T‑type calcium channel inhibitor ulixacaltamide met primary and key secondary endpoints in two pivotal Phase 3 trials for essential tremor. The...
Markets reward Praxis: shares triple after Phase 3 wins
The marketplace responded immediately to Praxis’ Phase 3 success: shares more than tripled intraday after the company disclosed positive topline results and plans for an NDA submission. Company...
Novo bankrolls Omeros: up to $2.1B for MASP‑3 rare‑disease antibody
Novo Nordisk licensed global rights to Omeros’ zaltenibart, a MASP‑3 blocking antibody targeting complement‑mediated rare blood and kidney disorders, in a deal that could reach $2.1 billion plus...
Aicuris to file NDA after Phase 3 win in refractory herpes
Aicuris Anti‑Infective Cures reported positive Phase 3 results for pritelivir in healing refractory herpes simplex virus lesions in immunocompromised patients and said it will prepare a U.S. NDA...
Tubulis lands $361M Series C – ADC push accelerates
Tubulis secured a $361 million Series C to accelerate clinical development of its antibody‑drug conjugate (ADC) pipeline and expand manufacturing and translational capabilities. The German...
Adcytherix raises €104M Series A to back ADC entry to clinic
French antibody developer Adcytherix closed a €105 million (about $122 million) Series A to take its lead ADC into first‑in‑human studies next year. The funding will support IND‑enabling work and...